Healthcare • NASDAQ
According to Zyberno, RadNet, Inc. (RDNT) is not a buy — WEAK BUSINESS (30/100) with a negative Margin of Safety of -6.8% and a Brina Gap of -30.4% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, RadNet, Inc. (RDNT) trades at $74.61 against an estimated intrinsic value per share of $69.88 — a -6.8% Margin of Safety based on Owner Earnings of $174.70M TTM, projected at 39.7% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -30.4% weakens the case: based on the company's ROIC (2.2%) and reinvestment rate (113.5%), the business can fundamentally grow at 2.5% — but the current enterprise value implies the market expects 32.9%. This places RDNT in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of 18.4% annually.
Over the trailing twelve months, RDNT generated $174.70M in Owner Earnings. Capital was deployed as follows: $234.35M invested in capital expenditures. Reinvestment rate: 113.5%. Owner Earnings have grown at 39.7% annually over the trailing five years using log-linear regression.